Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs

The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.